X0306 4 2018-11-12 0 0001505512 Regulus Therapeutics Inc. RGLS 0001703723 Witz Pascale C/O REGULUS THERAPEUTICS INC. 10614 SCIENCE CENTER DR SAN DIEGO CA 92121 1 0 0 0 Common Stock 2018-11-12 4 A 0 15833 A 19625 D Stock Option (Right to Buy) 17.40 2018-11-12 4 D 0 5000 D 2027-05-30 Common Stock 5000 0 D Stock Option (Right to Buy) 8.52 2018-11-12 4 D 0 6250 D 2028-05-16 Common Stock 6250 0 D Stock Option (Right to Buy) 8.76 2018-11-12 4 D 0 4583 D 2028-05-31 Common Stock 4583 0 D On November 12, 2018, the issuer canceled, pursuant to the issuer's option exchange program, the options listed below in Table II. In exchange for the options cancelled, the reporting person received Restricted Stock Units (RSUs) as reported in this Table I. The RSUs vest ratably on a quarterly basis, such that the the RSUs are fully vested one year after the date of grant, subject to the reporting person's continuous service to Regulus through each vesting date. Share numbers and exercise price reflect the 12-to-1 reverse stock split of the Issuer's common stock effective October 3, 2018. One third of the shares subject to the cancelled option would have vested on the one year anniversary of the date of grant and the balance of the shares would have vested in a series of 24 equal monthly installments thereafter, such that the option would have been fully vested on the third anniversary of the date of grant. On November 12, 2018, the issuer cancelled, pursuant to the issuer's option exchange program, the listed option. In exchange for the options cancelled, the reporting person received the Restricted Stock Units reported above in Table I. The cancelled option provided for vesting in 12 equal monthly installments commencing on the date of grant. The cancelled option vested in twelve equally monthly installments, such that the option would have been fully vested one year from the date of grant, or the date of the Company's next annual shareholder meeting, whichever occured first. Christopher Aker, Attorney in Fact 2018-11-13